“…Tegethoff and colleagues also advocate repeated measurements during the course of the disease; however, we do not think these additional timepoints would affect the predictive value of biomarkers from samples collected at baseline, which was the primary goal of our study. Finally, we are happy that our baseline study showed a positive association of C-X-C motif chemokines 10 with severe COVID-19, similar to that observed by Tegethoff and colleagues 5 during a longer timeframe. Overall, we agree that the path from discovery studies to clinical deployment involves several steps including further testing and validation, as noted both in our study 1 and by Tegethoff and colleagues.…”